Given the limited autoimmune ability and the degree of PD-1/PD-L1 expression, anti-PD-1/PD-L1 treatment was restricted to immunologically ‘cold’ tumors with few tumor-infiltration lymphocytes (TIL) [34–36]. This evidence concerns the gene PDCD1 and neoplasm.